Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of axitinib in treating nasopharynx cancer

A technology for axitinib and nasopharyngeal carcinoma, which is applied in the application field of axitinib in the treatment of nasopharyngeal carcinoma, and can solve atrophic fibrosis, radioactive dental caries, radioactive jaw osteomyelitis and radioactive cerebrospinal cord disease, decreased white blood cell count, tasteless or changed taste, etc., to achieve a solid clinical application foundation, good application prospects, and significant curative effect

Inactive Publication Date: 2017-12-15
SUN YAT SEN UNIV +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, radiation therapy may produce many complications: (1) Systemic reactions: including fatigue, dizziness, loss of appetite, nausea, vomiting, tasteless or bad taste in the mouth, insomnia or drowsiness, etc.
Individual patients may have blood changes, especially the decrease in white blood cell count; (2) Local reactions: including skin, mucous membrane, and salivary gland reactions; skin reactions manifest as dry dermatitis or even wet dermatitis, and mucosal reactions manifest as nasopharyngeal and oropharyngeal mucosal hyperemia , edema, exudation and accumulation of secretions, etc. In a small number of patients, parotid gland swelling can occur after 2Gy irradiation. When 40Gy is irradiated, the secretion of saliva is significantly reduced, and the secretion of oral mucosa is increased at the same time. Difficulty eating; ③Radiotherapy regression: mainly temporomandibular joint dysfunction, soft tissue atrophy and fibrosis, radiation caries, radiation-induced jaw osteomyelitis, and radiation-induced encephalomyelopathy, and there is no proper way to reverse it
[0004] Moreover, clinically, most of the patients are in the middle and late stage when they go to the doctor. For the cases of less differentiated cancer, late course of disease and recurrence after radiotherapy, recurrence often occurs even after regular treatment of nasopharyngeal carcinoma such as surgery, radiotherapy and chemotherapy. and transfer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of axitinib in treating nasopharynx cancer
  • Application of axitinib in treating nasopharynx cancer
  • Application of axitinib in treating nasopharynx cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Effect of axitinib on tube formation of vascular endothelial cells

[0025] 1. Experimental materials

[0026] (1) Drug: Axitinib, its chemical formula is: C22H18N4OS, and its CAS number is: 319460-85-0

[0027] (2) Vascular endothelial cells: human umbilical vein endothelial cells (HUVEC)

[0028] (3) Commercially available matrigel.

[0029] 2. Experimental grouping

[0030] (1) Control group: blank control, that is, HUVEC without any drug treatment.

[0031] (2) Experimental group: HUVEC were treated with axitinib.

[0032] 3. Angiogenesis assay to detect the effect of axitinib on HUVEC tube formation

[0033] (1) After thawing Matrigel at -20°C, spread 30 μL on a 96-well plate and place in a 37°C incubator for 30 minutes;

[0034] (2) Digest HUVEC cells in the logarithmic growth phase with trypsin and resuspend in the complete medium, take 200 μL (containing 5×10 4 Cells) were spread evenly on Matrigel matrigel in 96-well plate;

[0035] (3) Add ax...

Embodiment 2

[0039] Example 2 Effect of Axitinib on EBV-positive Nasopharyngeal Carcinoma Transplanted Tumor

[0040] 1. Experimental materials

[0041] (1) Drug: Axitinib

[0042] (2) Cancer cells: EBV-positive nasopharyngeal carcinoma cells (CNE2-EBV)

[0043] (3) Commercially purchased nude mice.

[0044] 2. Experimental grouping

[0045] (1) Control group: blank control, that is, the cancer cells were not treated with any drugs.

[0046] (2) Axitinib group: Axitinib was used to treat EBV-positive nasopharyngeal carcinoma cells.

[0047] 3. Subcutaneous tumor formation experiment in nude mice to detect the effect of axitinib on EBV-positive nasopharyngeal carcinoma cell xenografts

[0048] (1) with 5×10 6 Numerous EBV-positive nasopharyngeal carcinoma cells (CNE2-EBV) were implanted subcutaneously in the axilla of 40 NOD / SCID mice aged 3-4 weeks. They were randomly divided into 2 groups: blank control group and axitinib group.

[0049] (2) When the size of the subcutaneous tumor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of axitinib in treating nasopharynx cancer. The invention reports that axitinib is capable of remarkably inhibiting growth of nasopharynx cancer transplantation tumor and has a remarkable treatment effect on nasopharynx cancer for a first time. The invention provides novel application of axitinib, also provides a novel medicine for treating nasopharynx cancer, and has very good application prospects in preventing and treating nasopharynx cancer. In addition, axitinib is already a clinical medicine and has a solid clinical application foundation.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of Axitinib in the treatment of nasopharyngeal carcinoma. Background technique [0002] Nasopharyngeal carcinoma is one of the malignant tumors in my country, and its incidence rate is the first among malignant tumors of the ear, nose and throat. Most nasopharyngeal carcinomas are moderately sensitive to radiotherapy, and radiotherapy is the first choice for the treatment of nasopharyngeal carcinoma. [0003] However, radiation therapy may produce many complications: (1) Systemic reactions: including fatigue, dizziness, loss of appetite, nausea, vomiting, tasteless or bad taste in the mouth, insomnia or drowsiness, etc. Individual patients may have blood changes, especially the decrease in white blood cell count; (2) Local reactions: including skin, mucous membrane, and salivary gland reactions; skin reactions manifest as dry dermatitis or even ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61P35/00
CPCA61K31/4439
Inventor 向橦曾益新冯琳马文龙冯启胜何贵平
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com